Aquinox Pharma shares plunge more than 80%
The company’s shares dropped 85% to $2.34, being the lowest since Aug. 7, 2015. Rosiptor drug failed in meeting its goal of average change in reducing bladder pain in female patients by week 12 of the trial. According to the recent earnings report the company has not generated product revenue or profitability since its inception in 2003 and predicts it will keep incurring losses for the foreseeable future.
